These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29667200)

  • 1. Treatment in a preventive cardiology clinic utilizing advanced practice providers effectively closes atherosclerotic cardiovascular disease risk-management gaps among a primary-prevention population compared with a propensity-matched primary-care cohort: A team-based care model and its impact on lipid and blood pressure management.
    Fentanes E; Vande Hei AG; Holuby RS; Suarez N; Slim Y; Slim JN; Slim AM; Thomas D
    Clin Cardiol; 2018 Jun; 41(6):817-824. PubMed ID: 29667200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy.
    Figliuzzi I; Presta V; Citoni B; Miceli F; Simonelli F; Battistoni A; Coluccia R; Ferrucci A; Volpe M; Tocci G
    Clin Cardiol; 2018 Jun; 41(6):788-796. PubMed ID: 29604091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoption of coronary artery disease - Reporting and Data System (CAD-RADS™) and observed impact on medical therapy and systolic blood pressure control.
    Hull RA; Berger JM; Boster JM; Williams MU; Sharp AJ; Fentanes E; Maroules CD; Cury RC; Thomas DM
    J Cardiovasc Comput Tomogr; 2020; 14(5):421-427. PubMed ID: 32005447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
    Orringer CE
    Trends Cardiovasc Med; 2020 Apr; 30(3):151-157. PubMed ID: 31101399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report.
    Ferrario CM; Joyner J; Colby C; Exuzides A; Moore M; Simmons D; Bestermann W; Frech-Tamas F
    Vasc Health Risk Manag; 2013; 9():391-400. PubMed ID: 23901282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies.
    Rückert IM; Schunk M; Holle R; Schipf S; Völzke H; Kluttig A; Greiser KH; Berger K; Müller G; Ellert U; Neuhauser H; Rathmann W; Tamayo T; Moebus S; Andrich S; Meisinger C
    Cardiovasc Diabetol; 2012 May; 11():50. PubMed ID: 22569118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial.
    Östbring MJ; Eriksson T; Petersson G; Hellström L
    BMC Cardiovasc Disord; 2021 Aug; 21(1):367. PubMed ID: 34334142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MAURO study: baseline characteristics and compliance with guidelines targets.
    Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
    J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study.
    Shah Z; Masoomi R; Thapa R; Wani M; Chen J; Dawn B; Rymer M; Gupta K
    Cerebrovasc Dis; 2017; 44(3-4):150-159. PubMed ID: 28689200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comanagement of Risk Factors in Patients With Coronary Artery Disease: Insights From the APPEAR Study.
    Hejjaji V; Gosch K; Jones PG; Breeding T; Spertus JA; Arnold SV
    J Am Heart Assoc; 2020 Jun; 9(11):e015157. PubMed ID: 32441197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies.
    DeGuzman PB; Akosah KO; Simpson AG; Barbieri KE; Megginson GC; Goldberg RI; Beller GA
    Diab Vasc Dis Res; 2012 Apr; 9(2):138-45. PubMed ID: 22234950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cardiovascular risk factors after renal transplantation: a step towards reducing graft failure.
    Kumar R; Brar J; Yacoub R; Khan T; Zachariah M; Venuto R
    Transplant Proc; 2012 Jun; 44(5):1270-4. PubMed ID: 22663999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.